PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer
Recruiting · NCT06320223 · Observational (researchers observe without assigning treatment) · Lead sponsor: University Hospital, Essen
View the official record on ClinicalTrials.gov →What this trial is about
Background: PROMISE criteria have been defined for standardized reporting of Prostate-Specific Membrane Antigen (PSMA) PET whole-body stage of prostate cancer. PSMA PET disease extent by PROMISE has been associated with oncologic outcome. Need: Improved prognostication across various stages of prostate cancer is needed for management guidance and study design. Aim: 1. To assess the prognostic value of PSMA PET 2. To compare the prognostic value of PSMA PET with clinical prognostic scores in patients with prostate cancer at various disease stages Inclusion: * Adult patients with * biopsy/histo proven prostate cancer who * underwent PSMA PET (any type) * for staging or re-staging at any stage and who * have at least 3-year overall survival follow-up data available will be included consecutively. Exclusion: * Patients with neuroendocrine prostate cancer * Patients with metastasized or disseminated malignancy other than prostate cancer
Who can take part
Eligibility criteria (as published)
Where it is running
1 location listed.
- University Hospital Essen - Essen, Germany